Literature DB >> 15198476

Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.

Atsuhisa Sato1, Takao Saruta.   

Abstract

In recent years, it has been clarified that aldosterone can directly damage various organs, such as the heart, blood vessel, and kidneys, via non-epithelial mineralocorticoid receptors, independent of changes in blood pressure. Anti-aldosterone drugs have been clinically reported to be useful for their organ-protecting effects. The fact that these effects have been considered important for almost 10 years seems to indicate that aldosterone-induced organ damage can develop as a consequence of plasma aldosterone levels being in disproportion to salt status. In a previous study, cardiac fibrosis could not be induced in an experimental model of hyperaldosteronism with a low-salt diet. It is, therefore, extremely important to understand the relationship between plasma aldosterone level and inappropriate salt balance when considering diseases or states for which an anti-aldosterone drug is called for. In this paper we review the fundamental and clinical studies reported to date, mainly to investigate the pathology of organ damage induced by aldosterone and excess salt. Aldosterone-induced direct organ damage mediated through vasculitis essentially requires salt, which is inappropriate for plasma aldosterone level, and studies performed from this standpoint may provide a clue to the clarification of the involvement of salt in the actions of aldosterone via non-epithelial mineralocorticoid receptors. In humans, it is also strongly suggested that organ damage may occur, even at a plasma aldosterone level within a normal range, if salt intake is imbalanced to the aldosterone level. This means that the new aldosterone blocker eplerenone may also have significance as a drug inhibiting inflammation, possibly serving as a trigger of organ damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198476     DOI: 10.1291/hypres.27.303

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  16 in total

1.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Authors:  Eduardo Pimenta; Richard D Gordon; Ashraf H Ahmed; Diane Cowley; Rodel Leano; Thomas H Marwick; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

Review 2.  Resistant hypertension and aldosteronism.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 3.  Mineralocorticoid receptor blockade in chronic kidney disease.

Authors:  Matthew J Volk; Andrew S Bomback; Philip J Klemmer
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

Review 4.  New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.

Authors:  Irene Capelli; Lorenzo Gasperoni; Marco Ruggeri; Gabriele Donati; Olga Baraldi; Giovanni Sorrenti; Maria Turchese Caletti; Valeria Aiello; Giuseppe Cianciolo; Gaetano La Manna
Journal:  J Nephrol       Date:  2019-04-15       Impact factor: 3.902

5.  Predictors of resistant hypertension in an unselected sample of an adult male population in Italy.

Authors:  Antonio Barbato; Ferruccio Galletti; Roberto Iacone; Francesco P Cappuccio; Giovanni Rossi; Renato Ippolito; Antonella Venezia; Eduardo Farinaro; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2011-03-10       Impact factor: 3.397

Review 6.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

7.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

8.  Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism.

Authors:  Eduardo Pimenta; Michael Stowasser; Richard D Gordon; Susan M Harding; Michel Batlouni; Bin Zhang; Suzanne Oparil; David A Calhoun
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

9.  Disordered aldosterone-volume relationship in end-stage kidney disease.

Authors:  Andrew S Bomback; Abhijit V Kshirsagar; Maria E Ferris; Philip J Klemmer
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2009-10-28       Impact factor: 1.636

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.